What is Roth Capital's Estimate for CLRB Q1 Earnings?

Cellectar Biosciences, Inc. (NASDAQ:CLRB - Free Report) - Equities researchers at Roth Capital issued their Q1 2025 earnings per share (EPS) estimates for shares of Cellectar Biosciences in a research note issued on Monday, November 18th. Roth Capital analyst J. Aschoff anticipates that the biopharmaceutical company will post earnings per share of ($0.26) for the quarter. The consensus estimate for Cellectar Biosciences' current full-year earnings is ($1.57) per share.

CLRB has been the subject of a number of other research reports. Oppenheimer lowered their price target on Cellectar Biosciences from $14.00 to $12.00 and set an "outperform" rating for the company in a research report on Tuesday. StockNews.com upgraded Cellectar Biosciences to a "sell" rating in a research note on Thursday, September 26th.

Cellectar Biosciences Trading Up 0.3 %

Shares of CLRB traded up $0.01 during mid-day trading on Wednesday, hitting $1.62. The company's stock had a trading volume of 436,668 shares, compared to its average volume of 891,292. The firm has a 50-day simple moving average of $2.06 and a 200 day simple moving average of $2.41. The firm has a market capitalization of $65.52 million, a P/E ratio of -0.64 and a beta of 1.00. Cellectar Biosciences has a 1-year low of $1.57 and a 1-year high of $4.45.

Cellectar Biosciences (NASDAQ:CLRB - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($0.51) EPS for the quarter.

Hedge Funds Weigh In On Cellectar Biosciences

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in Cellectar Biosciences by 146.7% in the 1st quarter. Vanguard Group Inc. now owns 1,191,081 shares of the biopharmaceutical company's stock worth $4,741,000 after buying an additional 708,191 shares in the last quarter. Rosalind Advisors Inc. lifted its position in Cellectar Biosciences by 335.4% in the second quarter. Rosalind Advisors Inc. now owns 2,705,616 shares of the biopharmaceutical company's stock worth $6,764,000 after purchasing an additional 2,084,138 shares during the period. AIGH Capital Management LLC lifted its position in Cellectar Biosciences by 8.2% in the second quarter. AIGH Capital Management LLC now owns 3,036,187 shares of the biopharmaceutical company's stock worth $7,590,000 after purchasing an additional 231,270 shares during the period. XTX Topco Ltd lifted its position in Cellectar Biosciences by 432.4% in the second quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company's stock worth $158,000 after purchasing an additional 51,413 shares during the period. Finally, Sequoia Financial Advisors LLC acquired a new stake in Cellectar Biosciences in the third quarter worth approximately $51,000. 16.41% of the stock is owned by institutional investors.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.